NANOBIOTIX (NBTX) — FY2025 Results | Investor Summary
April 1, 2026
THE HEADLINE: INFLECTION YEAR, THESIS INTACT
FY2025 was a structural turning point — not a binary catalyst year, but a year that quietly de-risked the J&J acquisition thesis on multiple fronts: clinical breadth, financial discipline, and regulatory alignment. The bear case (dilution spiral, binary HNSCC bet, cash cliff) has been materially weakened.
5 REASONS TO STAY LONG
① Balance sheet transformed — without dilution The HCRx royalty deal ($71M, $50M already received) extended runway into early 2028. Cash of €52.8M at year-end vs €49.7M a year prior — they actually grew cash despite burning. No equity raise. For a micro-cap biotech, this is exceptional capital discipline.
② Net loss compressed 65% YoY €24M loss vs €68M in 2024. Revenue swung from -€7.2M to +€32.6M. The NANORAY-312 funding obligation removal (amendment with Janssen, March 2025) was the masterstroke — J&J now bears the Phase 3 cost, while NBTX retains milestone economics worth hundreds of millions.
③ Clinical data breadth de-risks binary risk JNJ-1900 data presented across 5 tumor types in 2025 (HNSCC, lung, pancreatic, esophageal, melanoma). Highlights:
- Esophageal: 85% DCR / 69% ORR (6 CRs) — striking response rates
- Pancreatic: mOS of 23 months from diagnosis in locally advanced/borderline resectable (historically grim indication)
- NSCLC re-irradiation: 64% 12-month local PFS, 83% OS — strong signals in a difficult population
- RM-HNSCC (anti-PD1 resistant): 74% DCR / 32% ORR in a population with zero good options
This is no longer a one-indication story. The physical mechanism of action thesis — works wherever radiotherapy works — is accumulating clinical proof points systematically.
④ NANORAY-312 sponsorship transfer = J&J skin in the game Transfer of Phase 3 sponsorship completed in Q4 2025. J&J now owns and drives the pivotal trial. This is not a licensor-licensee relationship anymore — it is a co-development partnership with the world's largest pharma funding the pivotal read. Alignment is total.
⑤ Curadigm Nanoprimer: optionality the market isn't pricing 4 new patents, first in vivo combo data (therapeutic vaccines), CMC activities launched, multiple MTAs signed. This platform is essentially a free call option on a second major nanotechnology franchise. Revenue contribution is 3–5 years out but IP is being built now.
KEY 2026 CATALYSTS TO WATCH
| Catalyst | Timing | Significance |
| CONVERGE (lung) Phase 1 data readout | Ongoing — first data Q1 2026 ✅ | Validates second lead indication |
| NANORAY-312 Phase 3 enrollment update | 2026 | Critical path to NDA/MAA |
| Pancreatic / esophageal Phase 1 updates | 2026 | Continued label expansion narrative |
| Melanoma anti-PD1 resistant data | 2026 | Immunotherapy combination signal |
| HCRx second tranche ($21M) | ~Dec 2026 | Milestone-gated non-dilutive cash inflow |
| Curadigm external collaboration announcements | 2026 | Re-rating catalyst if pharma partner disclosed |
FINANCIAL SNAPSHOT
| Metric | FY2025 | FY2024 | Δ |
| Revenue & other income | €32.6M | -€7.2M | n/m |
| R&D expenses | €23.1M | €40.5M | -43% |
| SG&A | €20.4M | €20.5M | -1% |
| Net loss | €24.0M | €68.1M | -65% |
| EPS | -€0.50 | -€1.44 | |
| Cash | €52.8M | €49.7M | +€3.1M |
Burn rate now manageable. With NANORAY-312 costs off P&L, underlying cash consumption is dramatically lower.
RISK FACTORS TO MONITOR
- NANORAY-312 timeline remains the single biggest variable — any delay from J&J side would defer milestone receipts
- HCRx second tranche conditionality — the $21M is not guaranteed; conditions must be met
- Regulatory re-classification (device → drug) in Europe accepted in Q3 2025 — a positive, but execution complexity remains
BOTTOM LINE
NBTX has successfully navigated from "speculative biotech" to "funded, multi-indication, J&J-partnered platform company" without diluting shareholders. The 2025 amendment was the defining strategic move — it transferred risk to J&J while preserving all milestone upside for NBTX. With cash through 2028, an active 2026 catalyst calendar, and a Curadigm platform that the market ignores entirely, the risk/reward for a long position remains asymmetrically favorable.Maintain conviction. Watch NANORAY-312 enrollment pace as the primary lead indicator.
For professional investors only. Does not constitute investment advice.